Quick Answer
AVAI BIO, INC. reported Operating Income Loss of -$1.14 million for the year ending 2025.
- AVAI BIO, INC. showed an increase of +46.3% in Operating Income Loss from 2024 to 2025.
- This data is from AVAI BIO, INC.'s annual report (Form 10-K), filed with the SEC on July 8, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $48.7 thousand | Q3 2020: -$50.5 thousand | Q4 2020: $417.2 thousand | Q2 2021: -$396.3 thousand | Q3 2021: $166.3 thousand | Q4 2021: $349.3 thousand | Q2 2022: $29.8 thousand | Q3 2022: $83.8 thousand | Q4 2022: $110.5 thousand | Q2 2023: $411.5 thousand | Q3 2023: $399.6 thousand | Q4 2023: $1.01 million | Q2 2024: -$528.8 thousand | Q3 2024: $623.0 thousand | Q4 2024: $452.3 thousand | Q2 2025: -$487.6 thousand | Q3 2025: -$453.0 thousand | Q4 2025: -$553.7 thousand.
- Over the full 7 years of available data (2019 to 2025), AVAI BIO, INC.'s Operating Income Loss has declined by 1,360.0%.
- Historical annual values: Fiscal year 2025: -$1.14 million | Fiscal year 2024: -$2.13 million | Fiscal year 2023: -$348.9 thousand | Fiscal year 2022: $126.5 thousand | Fiscal year 2021: $302.3 thousand | Fiscal year 2020: $69.6 thousand | Fiscal year 2019: -$78.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: